Goodwin advised Blueprint Medicines (NASDAQ: BPMC), on its underwritten public offering of 4,259,259 shares of its common stock at a public offering price of $81.00 per…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
